Stock Markets May 15, 2026 10:27 AM

POET Technologies Plummets After Short-Seller Report, Equity Offering and Mixed Q1 Results

Short-seller allegations, an equity sale, and a post-rally unwind combine to send POET shares sharply lower

By Marcus Reed POET

Shares of POET Technologies declined sharply in morning trading after a short-selling research note questioned the firm’s partnership claims and commercialization statements. The drop occurred amid concurrent developments: a federal securities class action over alleged misstatements about U.S. tax status, quarterly results that missed EPS estimates but exceeded revenue expectations, and a large registered direct offering that will issue more than 19 million shares plus warrants. The confluence of governance questions, dilution risk and post-rally profit-taking pressured the stock despite the company highlighting a major capital raise and an expanding AI partnership pipeline.

POET Technologies Plummets After Short-Seller Report, Equity Offering and Mixed Q1 Results
POET

Key Points

  • POET shares dropped 8.17% after a short-seller report accused the company of overstating partnerships and misleading commercialization claims.
  • Q1 2026 results showed GAAP EPS of -$0.08, missing estimates by $0.03, while revenue of $0.5 million rose 194.1% year-over-year and exceeded expectations.
  • POET agreed to sell 19,047,620 common shares and an equivalent warrant in a registered direct offering, and the Lumilens deal includes a warrant for up to 22.9 million shares, creating a notable dilution overhang.

POET Technologies shares fell 8.17% in morning trading following publication of a bearish short-seller report that accused the company of overstating key partnerships and of presenting misleading claims about product commercialization. The report added to an already complex situation for the company, which is facing a federal securities class action alleging it misrepresented its U.S. tax status as a likely Passive Foreign Investment Company (PFIC) and did not adequately disclose tax consequences for U.S. shareholders.

The short report also cited an internal comment from a senior figure at Celestial AI indicating that POET had not been discussed internally since 2023, a claim that the short seller said contradicts POET’s recent public partnership narrative. That allegation created fresh investor doubt about the depth and current relevance of POET’s customer relationships.

POET released first-quarter 2026 financial results the same day. The company reported GAAP earnings per share of -$0.08, missing consensus estimates by $0.03. Revenue for the quarter was $0.5 million, a 194.1% increase from the prior year and above revenue expectations. While the top-line growth beat forecasts, the earnings miss offered ammunition to sellers already looking for reasons to reduce exposure.

Compounding downward pressure, POET announced a definitive agreement to issue and sell 19,047,620 common shares and a warrant exercisable for an equivalent number of shares to a single institutional investor in a non-brokered registered direct offering. The offering represents a sizable immediate dilution to existing shareholders and was a primary factor cited by market participants reacting negatively to the stock.

Management changes were disclosed alongside the financing: POET confirmed the appointment of Sandeep Kumar as Chief Operating Officer and revealed that its chief financial officer plans to retire. That leadership transition introduced additional uncertainty about near-term execution at a time when governance and customer credibility were already under scrutiny.

The structure of the Lumilens agreement also contributed to investor concern. The deal includes a warrant that could be exercised for up to 22.9 million shares, a potential dilution overhang that market observers noted could limit upside for current holders even if the $500 million target tied to the agreement were realized.

The sharp pullback occurred after a dramatic recent run-up in POET stock. The shares more than doubled in roughly a week, including a nearly 30% jump on May 14 when the company announced a major supply agreement with Lumilens Inc., whose Optical Interposer platform aims to shrink, lower the cost of, and improve the power efficiency of optical components. That surge left the stock highly overbought, with the Relative Strength Index rising to 77 and the price moving well above both short-term and longer-term moving averages, increasing the risk of mean reversion.

Market context added to the challenge. The broader indices were down on the day, with the S&P 500 lower by 0.81%, the Dow Jones down 0.69%, and the NASDAQ off 1.14%, creating an unfavorable backdrop for high-beta, speculative technology names such as POET.

Beyond the short report and the financing, POET faces a stack of credibility and legal issues. Lawsuits allege PFIC misstatements and confidentiality breaches, and the company has been associated with the loss of all Celestial AI/Marvell orders, which together create a material overhang on its business credibility in the eyes of investors. The combination of negative short-seller allegations, an EPS miss, a large share issuance, and profit-taking after an extreme rally proved sufficient to overwhelm the stock’s recent gains.

At the same time, the company highlighted a planned $400 million capital raise and an expanding AI partnership pipeline. Nevertheless, the market reaction indicates that investors weighed the dilution risk, governance questions, and legal uncertainties more heavily than the potential runway afforded by new capital and partnerships.


Contextual takeaway - POET’s situation illustrates how governance concerns, tax complexity and contested customer relationships can collide with speculative enthusiasm in AI-related technology names. The current mix of accusations, legal actions, leadership changes, and financing activity has introduced significant uncertainty for shareholders and market participants evaluating the company’s near-term prospects.

Risks

  • Dilution risk from the registered direct offering and the Lumilens-related warrant could cap upside for shareholders and affect equity valuations - impacts the equity and technology sectors.
  • Legal and governance uncertainty, including a federal securities class action alleging PFIC misstatements and alleged confidentiality breaches, could weigh on investor confidence - impacts corporate governance assessments and investor relations in the tech sector.
  • Customer-relationship credibility concerns, highlighted by the short report’s claim regarding Celestial AI and reports of lost orders, pose execution and revenue risks - impacts revenue visibility in the AI and optical components supply chain.

More from Stock Markets

Starbucks to Cut About 300 U.S. Support Roles as It Reassesses International Support Structure May 15, 2026 Vida Global Lists on NYSE; Sells 3.75M Shares in $15M IPO May 15, 2026 Exxaro brings Matla mine expansion online to supply Eskom through 2043 May 15, 2026 Iran Conflict Redirects Crude Demand to Nigeria, Oando Executive Says May 15, 2026 Tel Aviv Benchmark Slides 2.08% as Financials and Insurers Weigh on Market May 15, 2026